ASX Announcement – 29 July 2022

QUARTERLY ACTIVITIES & CASHFLOW REPORT

Highlights

- High demand recorded for Resonance Health core-lab imaging services with sales volume for the quarter exceeding the March 2022 quarter and the prior corresponding June 2021 and 2020 quarters, and full-year 2022 sales volumes exceeding the 2021, 2020 (COVID-impacted), and 2019 full-year sales volumes.
- Onboarding and scanner verifications commenced for two new clinical trial service contracts secured in the March 2022 quarter, with these being in Resonance Health's two focus areas of iron overload and fatty liver disease. One of these is the first clinical trial contract secured in the large new Chinese market.
- Contract signed with new pharma customer to assist them with their clinical study Protocol for a phase 2A pharmaceutical clinical trial. The Company is investigating potential new growth avenues in its service provision offering(s) to pharmaceutical companies involved in clinical trials, in its core focus areas.
- Clinical trial service agreement extension agreed with existing Nasdaq-listed pharmaceutical company customer, for the extension of the provision of the Company's services for their clinical trial, for a further two years. The expected value of the extension, if the full extension term is completed, is A$537K.
- New clinical trial and commercial sales opportunities identified and advancing, via the Company's attendances and abstract presentations at The Annual International Liver Congress (22-26 June 2022), the European Hematology Congress (9-12 June 2022), and London Tech Week (13-17 June 2022).
- The adaptation and calibration of FerriScan® to newer generation 3.0 tesla (3T) MRI scanning machines progressed, with the Company's best-selling FerriScan® medical-device and service upgrade successfully completed, and made available to clinicians globally, from 25 July 2022 (post-period).
- Work to upgrade FerriSmart®, the AI evolution of FerriScan®, and the Company's Cardiac T2* device, to 3T MRI machines advanced. 3T MRI machines are being purchased in approx equal numbers (to 1.5T machines) in the USA and now account for 15-18% of MRI machines in Europe and North America.
- Availability of Resonance Health's software-as-medical-devices (SaMDs), including FerriScan®, on 3T MRI machines is a key element of Resonance Health's strategy to grow diagnostic and clinical trial contracts and revenue, with other Company SaMDs also being adapted and upgraded for newer 3T machines.
- Resonance Health's agreement with Chinese pharmaceutical company, Hanghzou-Zede Pharma-Tech Co, featured at the 35th Anniversary of the Western Australia–Zhejiang, China, Sister-State-Relationship Ceremony, and the Zhejiang, China, Health and Medical Life Sciences Sector Connect, on 31 May 2022.
- HepaFat-Scan® to be featured by Carpl.ai, the Company's new channel partner in India, in a study comparing HepaFat-Scan® with another fat assessment method, at the RSNA conference Nov-Dec 2022.
- AI functions, including development and support of SaMD-AI devices and enhancements, transitioned in-house from 3rd-party external contractor, with software dev team completing handover in June 2022. FerriSmart®, HepaFat-AI® and LiverSmart® now fully supported by in-house software dev + AI personnel.
- Continued progress on enhancement of SaMDs + services, aimed at broadening market access and enhancing patient and MRI centre integration, including a new AI device, CardiacT2*-AI, an AI version of the reg-cleared CardiacT2*, to complement the existing cleared FerriSmart®, HepaFat-AI® + LiverSmart®.

- R&D tax-incentive refund received on 1 July 2022 (post-period) in the amount of A$410K with the group cash balance on 29 July 2022, of approximately A$7 million. The group has zero debt.
- New Resonance Health website launched 24 July 2022 (post-period), see www.resonancehealth.com

Resonance Health Ltd (ASX: RHT) ("Resonance Health" or "Company") is pleased to release its Appendix 4C – Quarterly Activities & Cashflow Report for the quarter ended 30 June 2022.

FerriScan® now available on 3 tesla (3T) MRI machines

The Company progressed the development and enhancement of its existing imaging-based core-lab devices and services, with FerriScan®, the Company's flagship device, made available to clinicians globally on 3.0T MRI scanning machines, from 25 July 2022 (see ASX release dated 25 July 2022).

The gold standard in liver iron concentration measurement

FerriScan® is internationally recognised by clinicians as the gold standard for the measurement of liver-iron-concentration ("LIC") for patients suffering iron overload disorders. This accurate MRI-based technique is non-invasive and eliminates the need for liver biopsies. FerriScan® is recommended in multiple clinical patient management guidelines and international standards of care.

Since the Company's inception, Resonance Health has completed approximately 60,000 FerriScan® analyses to assist patients suffering iron overload disorders around the world. Until now, the FerriScan® service has only been available at MRI facilities with 1.5 tesla (1.5T) field strength MRI scanning machines.

Development of FerriScan® for 3T MRI machines

The Company commenced studies several years ago to adapt the FerriScan® acquisition protocol from 1.5T to 3T MRI scanners, allowing for better usability of the FerriScan® service across a broader range of MRI machines. Despite being technically challenging, Resonance Health recently successfully finalised the calibration of the FerriScan® protocol, and FerriScan® is now commercially available for use in clinical trials and in the routine clinical management of patients, on both 1.5T and 3T MRI machines.

Prevalence of 3T MRI machines and market opportunity

3T MRI machines offer advantages for clinicians and patients, including shorter scan times and greater image contrast compared with 1.5T MRI machines, and are growing in prevalence around the world. In the United States, 1.5T and 3T scanners are being purchased in approximately equal numbers and dominate new sales, with 3T scanners already representing approx. 15% to 18% of total MRI scanners in Europe and North America.[1]

Resonance Health is committed to ensuring its services, including FerriScan®, are at the forefront of technical development, including being calibrated across new generation MRI machines, enabling service availability to as many patients as possible, so that their diseases can be managed effectively by their treating physicians.

Ensuring that FerriScan® is available on as many MRI machines as possible is a key element of the Company's strategy to grow its clinical trial services contracts and revenue.

[1] Could Very Low Field Strength Be the Next Frontier for MRI?, Burhan Ahmed Khan, M.D., Hyperfine intern, Eliot L. Siegel, M.D., Associate Vice Chair, University of Maryland School of Medicine, *Diagnostic Imaging*, 11 March 2021

Further development - FerriSmart® for 3T

Work also continued to progress on the adaptation of FerriSmart®, the Company's Artificial Intelligence ("AI") evolution of FerriScan®, to 3T MRI scanning machines. This will further enhance availability and convenience for clinicians and patients in large new markets. Work also commenced on the adaptation and calibration of CardiacT2* to 3T machines, noting that many clinicians globally take advantage of the Company's bundled FerriScan® + CardiacT2* service, for a more holistic view of the patient's iron overload status.

Medical Device Enhancement & Development

Progress was made during the quarter towards completion of product innovations in existing SaMD medical devices + services, aimed at broadening market access, driving new market penetration, ensuring customer retention, and enhancing patient and MRI centre outcomes. Current priority projects include developing a new AI-assisted image analysis device, CardiacT2*-AI, an AI version of the Company's reg-cleared CardiacT2*, to complement Resonance Health's three existing AI devices; FerriSmart®, HepaFat-AI®, and LiverSmart®.

Once completed, the CardiacT2*-AI product is expected to provide real-time analysis to assist clinicians in assessing cardiac-iron levels, which has been identified by the Thalassaemia International Federation (TIF) as a critical and necessary requirement in large new markets where iron-overload diseases are prevalent. Through the Company's partnership with the Thalassaemia International Federation announced on 12 November 2021, clinicians in new markets are requesting this capability.

Other product innovation initiatives include the improvement of HepaFat-AI® via a new liver segmentation module, and the adoption of PDFF and steatosis outputs for HepaFat-Scan®. Work also continued validating a shorter MRI imaging protocol for FerriScan® and FerriSmart® with a potential 75% reduction in patient scanner time, thereby improving patient experience and increasing scanner throughput. This has now progressed successfully through the proof-of-concept stage.

Work continued developing new FAST software, the Company's job management software, with upgrades also completed on the legacy FAST software, notably with deployment of a new input-quality-control (IQC) module in FAST to improve and streamline workflow of the Company's highly trained analysts. Work also progressed on other initiatives to enhance and expand the Company's existing software-as-a-medical-device portfolio, including a potentially shortened MRI scanner sequence time for FerriScan® and FerriSmart®.

Newly contracted clinical trial services

Resonance Health continued the execution of key elements of its growth strategy, with new revenue streams to commence from two new clinical trial contracts signed in the March 2022 Quarter. These new contracts are for the provision of analytical services to companies undertaking clinical trials in the Company's two core disease markets of iron overload and fatty liver disease. One of these trials is the first clinical trial contract secured by the Company in the very large and underserviced Chinese market.

During the quarter Resonance Health was contracted by a new pharma customer to assist with their drafting of a clinical trial Protocol for a phase II pharmaceutical clinical trial. The Company is investigating potential new revenue growth avenues in its clinical trial service provision offering to pharmaceutical and therapeutic companies conducting clinical trials, in the Company's core focus areas and disease markets.

Approximately 38% of Resonance Health's revenue is derived from providing analysis and related services to pharmaceutical and therapeutic companies undertaking clinical trials for treatments of iron-overload and

liver-fat related disorders. Resonance Health is now providing services to 10 active clinical trials and has an active business development pipeline of further clinical trial prospects that it continues to pursue.

Resonance Health personnel are especially targeting growth in clinical trial services for potential new treatments for non-alcoholic steatohepatitis ("NASH"), a form of non-alcoholic fatty liver disease ("NAFLD"). Fatty-liver-disease is a major global health issue with international pharmaceutical companies seeking to develop effective drug treatments for the disease.

It is estimated that 24-30% of the global population suffers from NAFLD which roughly equates to 1.8-2.3 billion people. Of these, it is estimated that 20%, or 0.5 billion people, will also develop NASH which can cause liver damage including fibrosis and cirrhosis and which often requires immediate medical intervention. If the prevalence of NAFLD continues to rise in line with the global obesity epidemic, it is predicted that the healthcare burden of NAFLD over the next 10 years could increase to $1.005 trillion in the USA alone.

Clinical engagement + business development activities

New clinical trial and commercial sales opportunities were identified and advanced during the quarter, including via the Company attendance and presentation of abstracts at several conferences including the Digestive Disease Week (21-24 May 2022), The International Liver Congress (22-26 June 2022), the European Hematology Congress (9-12 June 2022), and London Tech Week (13-17 June 2022).

New clinical trial leads were pursued along with planning for the Company's potential future provision of enhanced and expanded CRO services and the possible future provision of core-wet-lab services, leveraging the Company's expertise and experienced personnel in molecular medicine, through the Company's molecular medicine R&D workstream.

The Company continued its new engagement in India with its newest channel partner, Carpl.ai, following signing of a partnership agreement with Carpl.ai in the March 2022 quarter. During the quarter, HepaFat-Scan® was featured by Carpl.ai, the Company's new channel partner in India, in a study comparing HepaFat-Scan® with another fat assessment method. This study was presented at a radiology conference in India. Work continued to deploy the Company's AI products on Carpl.ai's medical imaging solutions platform.

On 31 May 2022, Resonance Health's agreement, recently signed (in the March 2022 quarter) with Chinese pharmaceutical company, Hangzhou-Zede-Pharma-Tech Co, was featured at the 35th Anniversary of the Western Australia–Zhejiang, China, Sister-State-Relationship Ceremony, and at the related Zhejiang, China, Health and Medical Life Sciences Sector Connect. This agreement represents the Company's first entry into the very large under-serviced Chinese market, where iron-overload diseases are more prevalent.

Record-high sales volumes recorded

There was high demand for Resonance Health imaging device services during the quarter with core-lab sales volumes for the quarter exceeding both the March 2022 quarter and the prior corresponding June 2021 quarter, and full-year 2022 sales volumes exceeding both the 2021 and 2020 full-year sales volumes. The 2022 sales volumes also exceed the pre-COVID 2019 sales volumes. The Company is now targeting increased uptake of its highly scalable AI assisted services, through targeted sales and marketing campaigns managed through the Resonance Health CRM software platform.

AI and imaging R&D – LungSmart (Alert-PE) + Cystic-Fibrosis

A pre-submission meeting was held with the US Food & Drug Administration ("FDA") during the quarter, regarding the continued development of the LungSmart (formerly Alert-PE) medical device. LungSmart is an AI-assisted imaging analysis R&D project that analyses CTPA images of the lung in the case of patients with suspected pulmonary embolism ("PE"). The device has been trained on over 1,000 datasets provided via an agreement with Perth Radiological Clinic ("PRC").

Following the pre-submission meeting, the FDA has provided guidance on the next steps of development required for LungSmart, which includes using US board-certified radiologists to annotate data with region of interests (ROIs) identifying suspected filling defects, allowing for the device to have its statistical performance measured in a future clinical study.

The Company has also developed a cystic-fibrosis AI solution, with the Company to seek clinical partners to use the device for investigational purposes in their workflows as they relate to persons undergoing assessment or treatment of patients with suspected or confirmed cystic-fibrosis, or other lung conditions. The next stage of developmental work includes exploring the addition of trapped air as a reportable metric.

Molecular Medicine (ASO Project)

The molecular medicine R&D team has now completed the primary objectives of the initial phase of the ASO (antisense oligonucleotide) project, that being, to develop and validate a suite of 'cyclophilin-type specific' targeting drug molecules.

As previously reported, while the chosen lead AS3 molecule demonstrated strong antiviral activity in a cell-based model of Hepatitis B (conducted by the Doherty Institute) the results were not reflected in a follow-up limited proof-of-concept animal study. In reviewing the totality of data, the Company has decided to discontinue development of AS3 for Hepatitis B and will instead focus on other diseases of high unmet need.

The Company has now identified key liver and non-liver related diseases addressable with our suite of ASO drug molecules. To that end, the Company has developed associations with two well-funded groups undertaking advanced research in liver cancer and Alzheimer's disease. As these collaborations develop and mature, the Company will provide more detailed information.

Molecular Medicine (Blood Marker Project)

The Company is developing novel blood markers with the potential to provide cost-effective assessments of iron-overload and general liver-health for use in countries without ready access to MRI machines. Encouragingly, preliminary analysis of our validation set of blood samples from Vietnam and Turkey appear consistent with the original findings, and it is hoped this work will be completed within H2 2022.

New Resonance Health website

A new Resonance Health website went live on 24 July 2022 (post-period), see www.resonancehealth.com

Financial & Operating Performance

There was unprecedented demand for core-lab imaging device services with sales volumes for the quarter exceeding the March 2022 quarter and the prior corresponding June 2021, 2020 (COVID affected), and 2019 (pre-COVID) quarters. Full-year 2022 sales volume have exceeded both the 2021 and 2020 full-year volumes.

Chargeable analysis service volumes for Q4 FY2022 were 11% higher than the previous corresponding period in 2021, 131% higher than Q4 FY2020 (COVID affected), and 15% higher than Q4 FY2019 (pre-COVID).

Expenditure during the quarter included $313K in capitalised and non-capitalised R&D expenditure in relation to identified R&D priorities. Post-period, on 1 July 2022, the Company received an R&D tax-incentive refund of $410K with the Group cash balance at the end of July 2022, of $7 million. The Group has no debt.

Movements in exchange rates during the quarter positively impacted the Company's foreign currency cash holdings. This resulted in a positive movement in the balance of cash held during the quarter of $324K due to this factor, as recorded in item 4.5 in the attached quarterly cash flow.

With respect to item 6 of the Appendix 4C cash flow report for the quarter, payments to related parties of approximately $100K were made during the quarter. This comprised of $35K of remuneration paid to non-executive directors and $65K of remuneration paid to Mr Mitchell Wells as Managing Director.

This announcement has been authorised for release in accordance with the delegated authority of the Board of Directors of Resonance Health Limited.

For further information please contact:

Mitchell Wells – Managing Director
E: mitchellw@resonancehealth.com
P: +61 (0)8 9286 5300

Nick Allan – CFO & Company Secretary
E: nicholasa@resonancehealth.com
P: +61 (0)8 9286 5300

About Resonance Health

Resonance Health is an Australian healthcare technology and services company. The Company's services are used globally by clinicians in the management of human diseases and by pharmaceutical and therapeutic companies in their clinical trials. Resonance Health has gained endorsement by leading physicians worldwide for providing high quality quantitative assessments essential in the management of diseases.

Resonance Health's dedication to scientific rigour and quality management has enabled it to achieve regulatory clearances for a range of Software-as-Medical Devices (**SaMDs**) in the USA, Europe, UK, and Australia, and to proudly carry ISO 13485 certification for the design and manufacture of medical devices. The regulatory cleared SaMD products, some of which incorporate Artificial Intelligence (**AI**), include:

- **FerriScan®,** a core-lab product that provides an accurate assessment of liver iron concentration (**LIC**) through non-invasive MRI-based technology, for use in the assessment of individuals with iron overload conditions. Internationally recognised as the gold standard in LIC assessment.
- **FerriSmart®,** an AI-assisted, non-invasive MRI-based device for the automated real-time assessment of LIC in patients, calibrated against the global gold standard, FerriScan®.
- **HepaFat-Scan®,** an MRI-based solution which provides a reliable non-invasive assessment of liver-fat in liver tissue for use in the assessment of individuals with confirmed or suspected fatty-liver-disease.
- **HepaFat-AI®,** an AI-assisted, non-invasive device for the automated real-time multi-metric assessment of liver-fat in patients, for the assessment of individuals with confirmed or suspected fatty liver disease.
- **LiverSmart®,** an AI-assisted, non-invasive MRI-based multi-parametric device combining FerriSmart® and HepaFat-AI® into a consolidated report providing accurate assessment of LIC and liver fat.
- **CardiacT2*,** the most widely accepted MRI method for assessing heart iron loading. Resonance Health offers a dual analysis of FerriScan® and CardiacT2*. CardiacT2* is TGA and CE Marking regulatory cleared.
- **LiverSmart™**, combines FerriSmart® and HepaFat-AI® into a single multi-parametric MRI session, avoiding the need for multiple MRI appointments and delivering a more complete and comprehensive assessment of a person's liver.

The Company has an development pipeline of additional medical imaging analysis products and services, including **CardiacT2*-AI** an AI tool for the automated analysis and quantification of cardiac-iron levels and **LungSmart (Alert-PE™)**, an AI tool for the automated review of chest CT scans of patients with suspected PE.

Stakeholders, including clinicians, patients, and shareholders, are encouraged to register their interest at www.resonancehealth.com and to follow Resonance Health on Facebook, LinkedIn, and Twitter.

FOLLOW US

/Resonance-Health-Ltd /ResonanceHealth /ResonanceHealthLtd

Appendix 4C

Quarterly cash flow report for entities subject to Listing Rule 4.7B

Name of entity

Resonance Health Limited

ABN	**Quarter ended ("current quarter")**
96 006 762 492	30 June 2022

Consolidated statement of cash flows		**Current quarter $A'000**	**Year to date (12 months) $A'000**
1.	**Cash flows from operating activities**		
1.1	Receipts from customers	912	3,528
1.2	Payments for		
	(a) research and development	(147)	(688)
	(b) product manufacturing and operating costs		
	(c) advertising and marketing	(262)	(985)
	(d) leased assets		
	(e) staff costs	(726)	(2,433)
	(f) administration and corporate costs	(187)	(976)
1.3	Dividends received (see note 3)		
1.4	Interest received	1	5
1.5	Interest and other costs of finance paid		
1.6	Income taxes paid		
1.7	Government grants and tax incentives	25	25
1.8	Other (provide details if material)		
1.9	**Net cash from / (used in) operating activities**	**(384)**	**(1,524)**

2.	**Cash flows from investing activities**		
2.1	Payments to acquire or for:		
	(g) entities		
	(h) businesses		
	(i) property, plant and equipment	(8)	(119)
	(j) investments		
	(k) intellectual property	(145)	(585)
	(l) other non-current assets		

Consolidated statement of cash flows		Current quarter $A'000	Year to date (12 months) $A'000
2.2	Proceeds from disposal of:		
	(a) entities		
	(b) businesses		
	(c) property, plant and equipment		
	(d) investments		
	(e) intellectual property		
	(f) other non-current assets		
2.3	Cash flows from loans to other entities		
2.4	Dividends received (see note 3)		
2.5	Other (provide details if material)		
2.6	**Net cash from / (used in) investing activities**	**(153)**	**(704)**

3.	**Cash flows from financing activities**		
3.1	Proceeds from issues of equity securities (excluding convertible debt securities)		
3.2	Proceeds from issue of convertible debt securities		
3.3	Proceeds from exercise of options		
3.4	Transaction costs related to issues of equity securities or convertible debt securities		
3.5	Proceeds from borrowings		
3.6	Repayment of borrowings		
3.7	Transaction costs related to loans and borrowings		
3.8	Dividends paid		
3.9	Other (security deposit)	-	(37)
3.10	**Net cash from / (used in) financing activities**	**-**	**(37)**

4.	**Net increase / (decrease) in cash and cash equivalents for the period**		
4.1	Cash and cash equivalents at beginning of period	6,996	8,857
4.2	Net cash from / (used in) operating activities (item 1.9 above)	(384)	(1,524)
4.3	Net cash from / (used in) investing activities (item 2.6 above)	(153)	(704)

Consolidated statement of cash flows		Current quarter $A'000	Year to date (12 months) $A'000
4.4	Net cash from / (used in) financing activities (item 3.10 above)	-	(37)
4.5	Effect of movement in exchange rates on cash held	324	191
4.6	**Cash and cash equivalents at end of period**	**6,783**	**6,783**

5.	Reconciliation of cash and cash equivalents at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts	Current quarter $A'000	Previous quarter $A'000
5.1	Bank balances	5,762	5,975
5.2	Call deposits	1,021	1,021
5.3	Bank overdrafts		
5.4	Other (provide details)		
5.5	**Cash and cash equivalents at end of quarter (should equal item 4.6 above)**	**6,783**	**6,996**

6.	Payments to related parties of the entity and their associates	Current quarter $A'000
6.1	Aggregate amount of payments to related parties and their associates included in item 1	100
6.2	Aggregate amount of payments to related parties and their associates included in item 2	

Note: if any amounts are shown in items 6.1 or 6.2, your quarterly activity report must include a description of, and an explanation for, such payments.

7.	**Financing facilities** *Note: the term "facility' includes all forms of financing arrangements available to the entity.* *Add notes as necessary for an understanding of the sources of finance available to the entity.*	**Total facility amount at quarter end $A'000**	**Amount drawn at quarter end $A'000**
7.1	Loan facilities		
7.2	Credit standby arrangements		
7.3	Other (please specify)		
7.4	**Total financing facilities**		

7.5	**Unused financing facilities available at quarter end**	
7.6	Include in the box below a description of each facility above, including the lender, interest rate, maturity date and whether it is secured or unsecured. If any additional financing facilities have been entered into or are proposed to be entered into after quarter end, include a note providing details of those facilities as well.	

8.	**Estimated cash available for future operating activities**	**$A'000**
8.1	Net cash from / (used in) operating activities (item 1.9)	(384)
8.2	Cash and cash equivalents at quarter end (item 4.6)	6,783
8.3	Unused finance facilities available at quarter end (item 7.5)	
8.4	Total available funding (item 8.2 + item 8.3)	6,783
8.5	**Estimated quarters of funding available (item 8.4 divided by item 8.1)**	17.66

Note: if the entity has reported positive net operating cash flows in item 1.9, answer item 8.5 as "N/A". Otherwise, a figure for the estimated quarters of funding available must be included in item 8.5.

8.6 If item 8.5 is less than 2 quarters, please provide answers to the following questions:

8.6.1 Does the entity expect that it will continue to have the current level of net operating cash flows for the time being and, if not, why not?

Answer: N/A

8.6.2 Has the entity taken any steps, or does it propose to take any steps, to raise further cash to fund its operations and, if so, what are those steps and how likely does it believe that they will be successful?

Answer: N/A

8.6.3 Does the entity expect to be able to continue its operations and to meet its business objectives and, if so, on what basis?

Answer: N/A

Note: where item 8.5 is less than 2 quarters, all of questions 8.6.1, 8.6.2 and 8.6.3 above must be answered.

Compliance statement

1 This statement has been prepared in accordance with accounting standards and policies which comply with Listing Rule 19.11A.

2 This statement gives a true and fair view of the matters disclosed.

Date: 29 July 2022

Authorised by: By the Board of Directors of Resonance Health Limited

Notes

1. This quarterly cash flow report and the accompanying activity report provide a basis for informing the market about the entity's activities for the past quarter, how they have been financed and the effect this has had on its cash position. An entity that wishes to disclose additional information over and above the minimum required under the Listing Rules is encouraged to do so.

2. If this quarterly cash flow report has been prepared in accordance with Australian Accounting Standards, the definitions in, and provisions of, *AASB 107: Statement of Cash Flows* apply to this report. If this quarterly cash flow report has been prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the corresponding equivalent standard applies to this report.

3. Dividends received may be classified either as cash flows from operating activities or cash flows from investing activities, depending on the accounting policy of the entity.

4. If this report has been authorised for release to the market by your board of directors, you can insert here: "By the board". If it has been authorised for release to the market by a committee of your board of directors, you can insert here: "By the [*name of board committee – eg Audit and Risk Committee*]". If it has been authorised for release to the market by a disclosure committee, you can insert here: "By the Disclosure Committee".

5. If this report has been authorised for release to the market by your board of directors and you wish to hold yourself out as complying with recommendation 4.2 of the ASX Corporate Governance Council's *Corporate Governance Principles and Recommendations*, the board should have received a declaration from its CEO and CFO that, in their opinion, the financial records of the entity have been properly maintained, that this report complies with the appropriate accounting standards and gives a true and fair view of the cash flows of the entity, and that their opinion has been formed on the basis of a sound system of risk management and internal control which is operating effectively.